Spectral Medical Inc · TSX:EDT
Spectral Medical — Shareholder Meeting (June 2022)
19 slides from Spectral Medical's shareholder meeting presentation, Jun 20, 2022
Slide 1: 2022 AGM Presentation
2022 AGM Presentation June 20, 2022
Slide 2: Forward Looking Statements
Forward Looking Statements Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forward-looking information may relate to our future outlook and anticipated events or results and may include statements regarding our future fi
Slide 3: Executive Team Introduction
Executive Team Introduction Chris Seto Dr. John Kellum Sam Amory Blair McInnis CEO CMO President, Dialco CFO
Slide 4: Agenda
Agenda • Corporate Update • Clinical Environment Challenges: How we are overcoming and how we are moving forward o Tigris o Dialco and DIMI usability trial • Corporate Funding • Q&A 4 6/22/2022 Spectral Medical Inc.
Slide 5: Corporate Update
Corporate Update • Enrollment at 37 patients… data exceeding expectations Tigris • Tools to support enrollment in place • Baxter relationship… now keeping up with Baxter • DIMI usability trial… perception vs. reality Dialco • SAMI progressing… and an important bridge to DIMI • Equity Markets volatil
Slide 6: Tigris Update
Tigris Update 6 6/22/2022 Spectral Medical Inc.
Slide 7: Tigris Trial – Where are all the Sepsis patients?
Tigris Trial – Where are all the Sepsis patients? COVID had significantly impacted the Tigris trial; however, COVID not currently a factor in ICUs… … So where are all the sepsis patients? 7 6/22/2022 Spectral Medical Inc.
Slide 8: Tigris Trial – Where are all the Sepsis patients?
Tigris Trial – Where are all the Sepsis patients? Influenza is a large driver of sepsis • Since 2010, CDC estimates that flu has resulted in between 140,000 and 960,000 hospitalizations each year • 2022 Flu season: < 100,000 hospitalizations! • As a result, sepsis cases are down Are we missing cases
Slide 9: Patient Enrollment Initiatives
Patient Enrollment Initiatives 37 Patients enrolled and 14 open sites 2022 initiatives to increase patient enrollment: I. Working with FDA to increase # of sites to 25 – increase enrollment II. Sepsis cases increasing – enrollment increasing SOFA impact on enrollment: III. SOFA score protocol amendm
Slide 10: Tigris Trial – Timeline
Tigris Trial – Timeline Worst case Number of recruited patients *Due to COVID Omicron variant effects, the rates of 0.5, 0.75 and 1.0 begin in May 2022 and 15 sites Results to date exceed expectations and we continue to expect PMX will have a material impact on mortality benefit vs. standard of care
Slide 11: Baxter Relationship… Stronger Than Ever
Baxter Relationship… Stronger Than Ever • Relationship is beyond the initial quarterly ad hoc Joint Steering Committee o Previously characterized as a monitoring of Tigris Illustrative Financial Benefits to Spectral progress (in USD) Illustrative US Market Penetration of EDT Addressable Market (%) 7
Slide 12: Dialco Update
Dialco Update 12 6/22/2022 Spectral Medical Inc.
Slide 13: Dialco
Dialco SAMI… Grow the Acute dialysis business • Competitive and compelling offering… supported by an industry-leading SAMI team • Developing a robust commercial pipeline… ARC Dialysis is early evidence • Improve technology development process & implement customer requested improvements • Develop a s
Slide 14: DIMI Usability Trial
DIMI Usability Trial The usability trial is expected to evaluate 35 patients in a multi- phase settings in both in-center and in-home settings Est. Enrollment Timeline: 18-24 Months Est. First Site onboarded: Q322 Est. First Patient Enrolled: Q422
Slide 15: DIMI Usability Trial… Clinical Partner Activities
DIMI Usability Trial… Clinical Partner Activities • January 2022 announced FDA approval of DIMI trial protocol amendment • Actively in negotiations with clinical trial partners (sites) with HHD programs and wide geographical areas Clinical Partner Status: ‘Confirmed’ Site Selection Criteria ✓ Sites
Slide 16: Funding Update
Funding Update 16 6/22/2022 Spectral Medical Inc.
Slide 17: EDT Relative Share Price Performance
EDT Relative Share Price Performance EDT Relative Share Price Performance –YTD 2022 (June 17) 120% 100% 80% EDT +77% 60% 40% 20% 0% S&P/TSX (11%) -20% Russell 2000 (26%) Nasdaq Health (32%) -40% Cytosorbent (55%) -60% Outset (68%) -80% Source: Capital IQ 17 6/22/2022 Spectral Medical Inc.
Slide 18: Funding Activity
Funding Activity • Funding of Company bifurcated into two separate funding plans: i) Dialco direct investment; and ii) Spectral funding • Very distinct stories competing for distinct pools of capital • Potential to unlock shareholder value Dialco Spectral • Engaged Greenhill & Co. as financial advis
Slide 19: Q&A
Q&A Q&A 19 6/22/2022 Spectral Medical Inc.